ArticleTheranostics2016
A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma.
Article in Theranostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Complementary fluorescence and photoacoustic imaging of tozuleristide in muscle tissue in vitro- toward optically-guided solid tumor surgery: feasibility studies.Scientific reports · 2026Article
- A Novel Rat Model to Simulate Positive Margins in the Wound Bed of a Resected Sarcoma.Plastic and reconstructive surgery. Global open · 2024Article
- The LMIT: Light-mediated minimally-invasive theranostics in oncology.Theranostics · 2024Review
- Antitumor effects of targeted killing of tumor-associated macrophages under photothermal conditions.Lasers in medical science · 2022Article
- Intelligent optical diagnosis and treatment system for automated image-guided laser ablation of tumors.International journal of computer assisted radiology and surgery · 2021Article
- Combined Nd:YAG and Er:YAG lasers for real-time closed-loop tissue-specific laser osteotomy.Biomedical optics express · 2020Article
- Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer.American journal of nuclear medicine and molecular imaging · 2019Article
- Dual-modality optical diagnosis for preciseTheranostics · 2019Article
- A novel integration of spectral-domain optical-coherence-tomography and laser-ablation system for precision treatment.International journal of computer assisted radiology and surgery · 2018Article
- Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.Journal of personalized medicine · 2018Review
- Can "Indirect" Contact Laser Surgery be Used for Fluorescence-Image Guided Tumor Resections? Preliminary Results.Technology in cancer research & treatment · 2018Article
- Bioluminescence imaging and two-photon microscopy guided laser ablation of GBM decreases tumor burden.Theranostics · 2018Article
- A Novel Imaging System Distinguishes Neoplastic from Normal Tissue During Resection of Soft Tissue Sarcomas and Mast Cell Tumors in Dogs.Veterinary surgery : VS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
The treatment of soft tissue sarcoma (STS) generally involves tumor excision with a wide margin. Although advances in fluorescence imaging make real-time detection of cancer possible, removal is limited by the precision of the human eye and hand. Here, we describe a novel pulsed Nd:YAG laser ablation system that, when used in conjunction with a previously described molecular imaging system, can identify and ablate cancer in vivo. Mice with primary STS were injected with the protease-activatable probe LUM015 to label tumors. Resected tissues from the mice were then imaged and treated with the laser using the paired fluorescence-imaging/ laser ablation device, generating ablation clefts with sub-millimeter precision and minimal underlying tissue damage. Laser ablation was guided by fluorescence to target tumor tissues, avoiding normal structures. The selective ablation of tumor implants in vivo improved recurrence-free survival after tumor resection in a cohort of 14 mice compared to 12 mice that received no ablative therapy. This prototype system has the potential to be modified so that it can be used during surgery to improve recurrence-free survival in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.